510(k) device
Orion
Interacoustics A/S · Apparatus, Vestibular Analysis (LXV, Unclassified) · First FDA decision Aug 12, 2020, newest Aug 12, 2020
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
20
Naming "Orion"
MAUDE reports
2,646
Brand "Orion", since 2015
PubMed studies
1,100
Mentioning "Orion"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Orion510(k)
K200529 · Decided Aug 12, 2020 · 163 days after receipt
Device type: Apparatus, Vestibular Analysis (LXV) · Otolaryngology (ENT)
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Human Chorionic GonadotropinNational determinationOn the books190.27Updated Oct 1, 2026
- Human Chorionic Gonadotropin (Addition of ICD-9-CM Code 158.9, Malignant Neoplasm of Peritoneum, Unspecified)Coding analysisReview closedCAG-00372NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Orion", any status and sponsor, newest update first.
- Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound ManagementPivotal-lookingActive, not recruiting
Legacy Medical ConsultantsNot on our public-company list
NCT06420245 · 240 participants (planned) · Start Dec 30, 2025 · Primary completion Nov 2026
Device: Orion TM Amniotic Membrane Allograft · For: Diabetic Foot Ulcer
Sites: Palm Springs, California; San Francisco, California; Vista, California · 8 sites in all
- Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION)Pivotal-lookingCompleted
Walailak UniversityAcademic, hospital or other
NCT06377007 · 144 participants · Start May 1, 2024 · Primary completion Jan 31, 2025
Device: IOLMaster 700 (Carl Zeiss Meditec AG); ARGOS (Movu/Santec; distributed by Alcon) · For: Cataract
Sites: Nakhon Si Thammarat, Thailand
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT04305925 · 10 participants · Start Jan 30, 2020 · Primary completion Jan 30, 2023
Device: Focal Laser Ablation · For: Prostate Cancer
Sites: Los Angeles, California
- Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social InteractionActive, not recruiting
Shirley Ryan AbilityLabAcademic, hospital or other
NCT03204513 · 15 participants (planned) · Start Dec 2016 · Primary completion Dec 2026
Device: Vanderbilt Powered Knee-Ankle Prosthesis; Microprocessor (MP) Knee Prosthesis · For: Transfemoral Amputees
Sites: Chicago, Illinois
The Cleveland ClinicAcademic, hospital or other
NCT04835844 · 49 participants · Start Jul 24, 2020 · Primary completion Jul 11, 2025
Device: CARTO; RHYTHMIA · For: Paroxysmal Atrial Fibrillation
Sites: Cleveland, Ohio
Sight Sciences, Inc.Not on our public-company list
NCT04872348 · 28 participants · Start Jul 1, 2021 · Primary completion Nov 2, 2023
Device: OMNI® Surgical System · For: Glaucoma, Open-Angle
Sites: Atlanta, Georgia; Wichita, Kansas; Bloomington, Minnesota · 10 sites in all
University of BolognaAcademic, hospital or other
NCT04582799 · 0 participants · Start Aug 1, 2024 · Primary completion Aug 1, 2024
Device: ECCO2R; NIV · For: Pulmonary Disease, Chronic Obstructive
Hospital General de México Dr. Eduardo LiceagaGovernment (non-federal)
NCT06622538 · 50 participants · Start Oct 1, 2024 · Primary completion Oct 15, 2024
Device: Orotracheal intubation · For: Orotracheal Intubation; Videolaryngoscopes (VL); 3D Printing and 1 more
Sites: Mexico City, Mexico
- Early Feasibility Study of the Orion Visual Cortical Prosthesis SystemActive, not recruiting
Second Sight Medical ProductsNot on our public-company list
NCT03344848 · 6 participants (planned) · Start Nov 20, 2017 · Primary completion Mar 31, 2025
Device: Orion Visual Cortical Prosthesis System · For: Blindness, Acquired
Sites: Los Angeles, California; Houston, Texas
Orion Biotech Inc.Not on our public-company list
NCT06532968 · 30 participants · Start Mar 30, 2022 · Primary completion May 22, 2024
Device: Sham; ORION spinal lamina cover · For: Degenerative Lumbar Spinal Stenosis; Degenerative Spondylolisthesis; Spinal Stenosis and 2 more
Sites: Taipei, Taiwan
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Orion", and for the whole product code for context.
This brand
2,646 reports: 333 malfunction, 2,286 injury, 24 death
Whole product code LXV
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- Orion RC SCS IPGInjury
1627487-2026-10960 · Received Oct 29, 2026 · Event dated Oct 1, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Unspecified Infection
- Orion RC SCS IPGInjury
1627487-2026-10901 · Received Oct 28, 2026 · Event dated Sep 29, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Implant Pain
- Orion RC SCS IPGInjury
1627487-2026-10902 · Received Oct 28, 2026 · Event dated Sep 30, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Implant Pain
- Orion RC SCS IPGInjury
1627487-2026-10905 · Received Oct 28, 2026 · Event dated Oct 1, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Improper or Incorrect Procedure or Method
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Orion RC SCS IPGInjury
1627487-2026-10916 · Received Oct 28, 2026 · Event dated Sep 30, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Wireless Communication Problem
Patient problem as coded: Inadequate Pain Relief
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Orion"[tiab]. The summary above synthesizes these.
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK, Wright RS, Kallend D, et al. · N Engl J Med · 2020Clinical Trial, Phase III, Multicenter Study
- JCAHO/Orion.
Rogers HL · J Med Assoc Ga · 1996
- Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK, Troquay RPT, Visseren FLJ, et al. · Lancet Diabetes Endocrinol · 2023Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- Darolutamide: First Approval.
Markham A, Duggan S · Drugs · 2019Review
- ORION-8: one step closer to understanding the safety and efficacy of inclisiran.
Tokgözoğlu L, Norata GD · Cardiovasc Res · 2024Editorial, Comment
- The Drosophila chemokine-like Orion bridges phosphatidylserine and Draper in phagocytosis of neurons.
Ji H, Wang B, Shen Y, et al. · Proc Natl Acad Sci U S A · 2023Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- ORION-3: delivering lipid lowering treatment for longer.
Nicholls SJ · Lancet Diabetes Endocrinol · 2023Comment
- Shooting for multiplexed pathology with Orion.
Anderson AN, Gibbs SL · Nat Cancer · 2023
- ORION software tool for the geometrical calibration of all-sky cameras.
Antuña-Sánchez JC, Román R, Bosch JL, et al. · PLoS One · 2022Research Support, Non-U.S. Gov't
- Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18.
Huo Y, Lesogor A, Lee CW, et al. · JACC Asia · 2024
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
Wright RS, Collins MG, Stoekenbroek RM, et al. · Mayo Clin Proc · 2020Clinical Trial, Phase I, Clinical Trial, Phase II
- Insights from ORION studies: focus on inclisiran safety.
Catapano AL, Pirillo A, Norata GD · Cardiovasc Res · 2021Editorial, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LXV.
- GyroStimUltrathera Technologies, Inc. · 510(k) 2022
- TrvInteracoustics A/S · 510(k) 2020
- ClearEdge Balance SystemQuadrant Biosciences · 510(k) 2019
- EQ BalanceUpright Science, Inc. · 510(k) 2019
- K-D BalanceKing-Devick Technologies, Inc. · 510(k) 2018
- Vestibular Analysis ApparatusCapacity Sports, LLC · 510(k) 2012
- Nydiag 200Interacoustics A/S · 510(k) 2010
- Vertigone Bppv GoggleVertigone, Inc. · 510(k) 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.